Augmentation Cystoplasty near Bridgeport, CT

Care Philosophy: Urologic oncology is a multidisciplinary field that incorporates innovative surgical technology, systemic treatments such as chemotherapy as well as a focused research effort. As a Professor of Urology and the Clinical Director of Urologic Oncology I continually interact with colleagues in areas of medical oncology, radiation oncology, pathology among others in order to provide the most comprehensive and innovative care for our patients with prostate, bladder, kidney and testicular cancer. Advances in robotic technology along with scientific progress in our precision medicine program have allowed us to direct therapy in unprecedented ways. As a leader in this area I look forward to continued advances in this exciting and challenging field.

Biography: James McKiernan, MD, is the John K. Lattimer Professor of Urology, and CEO, of ColumbiaDoctors. He also is the interim dean of Columbia University Vagelos College of Physicians and Surgeons. Dr. McKiernan graduated from Johns Hopkins University with a BA in biology and received his MD from Columbia University College of Physicians and Surgeons. He completed his training in urology and general surgery at NewYork-Presbyterian Hospital, followed by a urologic surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. McKiernan's clinical practice is focused on urologic oncology and particularly on surgical therapy in high-risk patients with bladder and kidney cancers. Dr. McKiernan evaluates and treats over 1,000 patients with bladder cancer every year. His research, funded by NIH and biotechnology industry grants, focuses on developing novel therapeutics for bladder cancer treatment as well as comparative effectiveness research in urologic oncology. In the management of kidney and bladder cancer, he has special expertise in organ preservation and reconstructive surgery to maximize quality of life. Dr. McKiernan's research has been published in Cancer, Cancer Research, the Journal of Clinical Oncology, JAMA Oncology, Journal of Urology, Urologic Oncology, and Urology. He has authored and co-authored more than 220 scientific articles and book chapters on urologic cancer and related issues. For the past 10 years, he has directed a research team at Columbia University Medical Center investigating quality outcomes and effectiveness in urologic cancer surgery. He has served as the Vice Chairman for the AJCC TNM Staging Task Force, Co-Chair of the AUA Guidelines Panel on non-muscle invasive bladder cancer, as well as on the American Board of Urology and Society of Urologic Oncology Examination Committees. In addition, Dr. McKiernan is the principal investigator of the NIH-funded clinical trials program of experimental therapeutics in bladder cancer at Columbia University/NYPH, which is investigating new agents for bladder preservation in patients whose cancer has recurred after standard therapy. In collaboration with researchers at Columbia's Herbert Irving Comprehensive Cancer Center, his team continues to develop new therapeutic strategies for managing bladder cancer.

Biography: Dr. Philippa Cheetham, MD is an Urology Specialist who practices in Mineola, NY. She has been practicing for 29 years. Dr. Philippa Cheetham, MD is affiliated with Mount Sinai Hospital.

Biography: Dr. Susan Marshall, MD is an Urology Specialist who practices in New York, NY. She is 43 years old and has been practicing for 17 years. Dr. Susan Marshall, MD is affiliated with Mount Sinai Morningside, Mount Sinai Hospital and Mount Sinai Queens.